Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Genmab has a “Moderate Buy” consensus rating from 13 analysts: nine buys, three holds, and one strong buy. The average 12-month price target is $39.50, above the reported $33.60 share price.
• Recent analysts remained positive, with HC Wainwright and Guggenheim raising their price targets to $40 and $42, respectively; Truist also initiated coverage with a buy rating and a $40 target.
• Genmab exceeded quarterly expectations, reporting $0.54 in EPS versus a $0.37 consensus and revenue of $1.16 billion versus estimates of $1.12 billion. Institutional investors own 7.07% of the company, with several firms increasing their holdings.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) has earned an average rating of "Moderate Buy" from the thirteen ratings firms that are covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $39.50.

Several research analysts recently weighed in on GMAB shares. Weiss Ratings raised Genmab A/S from a "hold (c)" rating to a "hold (c+)" rating in a research report on Tuesday. HC Wainwright increased their price target on shares of Genmab A/S from $38.00 to $40.00 and gave the stock a "buy" rating in a research report on Thursday, July 2nd. Truist Financial started coverage on shares of Genmab A/S in a research report on Wednesday, May 27th. They issued a "buy" rating and a $40.00 target price for the company. New Street Research set a $43.00 target price on shares of Genmab A/S in a research note on Wednesday, July 22nd. Finally, Guggenheim boosted their target price on Genmab A/S from $40.00 to $42.00 and gave the company a "buy" rating in a research note on Friday, August 7th.

Institutional Investors Weigh In On Genmab A/S

Large investors have recently made changes to their positions in the company. Knollwood Investment Advisory LLC bought a new stake in Genmab A/S in the second quarter worth approximately $201,000. Syon Capital LLC raised its holdings in Genmab A/S by 39.5% during the second quarter. Syon Capital LLC now owns 11,023 shares of the company's stock valued at $303,000 after buying an additional 3,123 shares in the last quarter. Nykredit A S bought a new position in Genmab A/S during the second quarter valued at about $58,000. Headlands Technologies LLC boosted its stake in shares of Genmab A/S by 108.7% during the 2nd quarter. Headlands Technologies LLC now owns 27,141 shares of the company's stock worth $746,000 after acquiring an additional 14,138 shares in the last quarter. Finally, Legacy Wealth Asset Management LLC increased its holdings in shares of Genmab A/S by 164.1% during the 2nd quarter. Legacy Wealth Asset Management LLC now owns 102,164 shares of the company's stock valued at $2,806,000 after acquiring an additional 63,484 shares during the last quarter. Institutional investors own 7.07% of the company's stock.

Genmab A/S Stock Performance

GMAB opened at $33.60 on Friday. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. The firm has a market cap of $20.96 billion, a PE ratio of 26.46, a P/E/G ratio of 1.99 and a beta of 0.84. The business has a fifty day simple moving average of $30.47 and a 200-day simple moving average of $28.14. Genmab A/S has a fifty-two week low of $23.62 and a fifty-two week high of $35.43.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.54 EPS for the quarter, beating analysts' consensus estimates of $0.37 by $0.17. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.12 billion. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. As a group, equities analysts predict that Genmab A/S will post 1.17 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company's work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab's portfolio includes products developed in collaboration with leading global pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source